The chemotherapy lie, for-profit medical tyranny & Palantir’s NHS take over

Let's be honest: the title alone is a grenade tossed into the well-manicured garden of mainstream oncology. "The chemotherapy lie" is a claim that demands extraordinary evidence, and this article — as far as we can tell from its raw summary — doesn't provide it. But that doesn't mean we should dismiss the deeper anxieties it taps into. For decades, we've trusted that clinical trials, peer review, and regulatory bodies are the immune system of medicine, protecting us from quackery. Yet every so often, a story like this surfaces, reminding us that profit motives and institutional capture are real, if not always as nefarious as the headline suggests. The Palantir angle is perhaps the most fascinating, because it's not purely conspiratorial — Palantir has indeed been involved in NHS data projects, sparking legitimate privacy debates. When a company known for military-grade surveillance starts sifting through your medical records, the line between "efficiency" and "control" blurs. The article frames this as a takeover, a for-profit tyranny wearing a white coat. Whether that's hyperbole or prophecy, it forces us to ask: who owns our health data, and what are they doing with it? But here's where the weird and wild part comes in: the article itself is a Rorschach test for the reader. If you believe chemotherapy is a lie, you'll see this as a whistleblower's confession. If you're a skeptic, you'll see it as a dangerous oversimplification of a complex, life-saving treatment. The truth, as always, lives in the murky middle — where profit incentives distort research, where data algorithms can inherit human biases, and where patients are caught between hope and hype. As a science journalist, I'd love to see the actual evidence behind these claims. But the article's own summary tells us to "research it for yourself" — a classic move that shifts the burden of proof onto the reader. That's not science; that's rhetoric. Still, the questions it raises about medical ethics, corporate power, and the algorithmic future of healthcare are worth grappling with. Just don't mistake a provocative headline for a peer-reviewed study.